Adult and juvenile dermatomyositis treatment

被引:5
作者
Patil, Anant [1 ]
Lu, Jun [2 ]
Kassir, Martin [3 ]
Babaei, Mahsa [4 ]
Goldust, Mohamad [5 ]
机构
[1] Dr DY Patil Med Coll, Dept Pharmacol, Navi Mumbai, India
[2] UConn Hlth Dept Dermatol, Farmington, CT USA
[3] Worldwide Laser Inst, Dallas, TX USA
[4] Shahid Beheshti Univ Med Sci, Tehran, Iran
[5] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany
关键词
corticosteroids; dermatomyositis; immunosuppressants; malignancy; management; REFRACTORY ADULT; POLYMYOSITIS; RITUXIMAB;
D O I
10.1111/jocd.15363
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction Dermatomyositis is a rare autoimmune inflammatory condition affecting skin and muscles. The disease can be seen in both adults and children. It can be associated with malignancy. Considering involvement of skin in the disease, many patients consult dermatologists for its treatment. Hence, knowledge about its presentation, complications, prognosis, and treatment is necessary. Objective The objective of this review article is to provide comprehensive information about treatment of dermatomyositis. Methods In this review article, we reviewed the published literature on adult and juvenile dermatomyositis to highlight the treatment. Articles published in peer-reviewed journals including reviews, clinical trials, case series, and case reports published in electronic database (MEDLINE/PubMed) through January 2021, cross references of respective articles and trials from were included for qualitative analysis of the literature. Results Treatment options for dermatomyositis include traditional immunosuppressive agents and immunomodulatory therapy. High-dose corticosteroids represent the first line of treatment while other immunosuppressive agents are also used, either in combination with or as an alternative to corticosteroids, after initial treatment failure. Some biological agents have been used for the treatment of dermatomyositis with variable responses. Conclusion Although several treatment options are available, several questions remain unanswered about the optimal treatment of dermatomyositis.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 50 条
  • [21] Biologika zur Therapie der juvenilen DermatomyositisBiologicals for the treatment of juvenile dermatomyositis
    G. Horneff
    Monatsschrift Kinderheilkunde, 2007, 155 : 111 - 117
  • [22] Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis
    Preusse, Corinna
    Allenbach, Yves
    Hoffmann, Olaf
    Goebel, Hans-Hilmar
    Pehl, Debora
    Radke, Josefine
    Doeser, Alexandra
    Schneider, Udo
    Alten, Rieke H. E.
    Kallinich, Tilmann
    Benveniste, Olivier
    von Moers, Arpad
    Schoser, Benedikt
    Schara, Ulrike
    Stenzel, Werner
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2016, 4 : 45
  • [23] Environmental factors associated with disease flare in juvenile and adult dermatomyositis
    Mamyrova, Gulnara
    Rider, Lisa G.
    Ehrlich, Alison
    Jones, Olcay
    Pachman, Lauren M.
    Nickeson, Robert
    Criscone-Schreiber, Lisa G.
    Jung, Lawrence K.
    Miller, Frederick W.
    Katz, James D.
    RHEUMATOLOGY, 2017, 56 (08) : 1342 - 1347
  • [24] Juvenile Dermatomyositis and the Inflammatory Myopathies
    Swafford, Collin
    Roach, E. Steve
    SEMINARS IN NEUROLOGY, 2020, 40 (03) : 342 - 348
  • [25] Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis
    Ward, James M.
    Ambatipudi, Mythri
    O'Hanlon, Terrance P.
    Smith, Michael A.
    de Los Reyes, Melissa
    Schiffenbauer, Adam
    Rahman, Saifur
    Zerrouki, Kamelia
    Miller, Frederick W.
    Sanjuan, Miguel A.
    Li, Jian-Liang
    Casey, Kerry A.
    Rider, Lisa G.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (11) : 2014 - 2026
  • [26] ADULT-ONSET POLYMYOSITIS-DERMATOMYOSITIS - DESCRIPTION OF 25 PATIENTS WITH EMPHASIS ON TREATMENT
    RAMIREZ, G
    ASHERSON, RA
    KHAMASHTA, MA
    CERVERA, R
    DCRUZ, D
    HUGHES, GRV
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1990, 20 (02) : 114 - 120
  • [27] Favorable outcomes with reduced steroid use in juvenile dermatomyositis
    Orandi, Amir B.
    Fotis, Lampros
    Lai, Jamie
    Morris, Hallie
    White, Andrew J.
    French, Anthony R.
    Baszis, Kevin W.
    PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
  • [28] Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis
    Yildirim, Deniz Gezgin
    Baglan, Esra
    Gungorer, Vildan
    Yildiz, Cisem
    Tuncez, Serife
    Bulbul, Mehmet
    Acar, Banu
    Bakkaloglu, Sevcan A.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (08) : 1504 - 1511
  • [29] Macrophage activation syndrome in adult dermatomyositis: a case-based review
    Kishida, Dai
    Sakaguchi, Noriko
    Ueno, Ken-ichi
    Ushiyama, Satoru
    Ichikawa, Takanori
    Yoshinaga, Tsuneaki
    Shimojima, Yasuhiro
    Sekijima, Yoshiki
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (07) : 1151 - 1162
  • [30] Comparison between treatment naive juvenile and adult dermatomyositis muscle biopsies: difference of inflammatory cells phenotyping
    Samuel Katsuyuki Shinjo
    Adriana Maluf Elias Sallum
    Sueli Mieko Oba-Shinjo
    Marilda Guimarães Silva
    Clovis Artur Silva
    Suely Kazue Nagahashi Marie
    Advances in Rheumatology, 58